Literature DB >> 8203845

Pharmacokinetics of antiviral polyoxometalates in rats.

L Ni1, F D Boudinot, S G Boudinot, G W Henson, G E Bossard, S A Martellucci, P W Ash, S P Fricker, M C Darkes, B R Theobald.   

Abstract

Polyoxometalates are soluble mineral compounds formed principally of oxide anions and early transition metal cations. The polyoxometalates K12H2[P2W12O48].24H2O (JM 1591), K10[P2W18Zn4(H2O)2O68].20H2O (JM 1596), and [(CH3)3NH]8[Si2W18Nb6O77] (JM 2820) demonstrate potent antiviral activity against human immunodeficiency virus types 1 and 2, herpes simplex virus, and cytomegalovirus in vitro. The preclinical pharmacokinetics of these three compounds were characterized after single-dose intravenous administration of 50 mg/kg to rats. Plasma, urine, and feces were collected for 168 h, and polyoxometalate concentrations were determined by atomic emission. Serum protein binding was measured by equilibrium dialysis. All three compounds were highly bound to serum proteins in a concentration-dependent manner. Total and unbound concentrations of the three compounds in plasma declined in a triexponential manner with terminal half-lives of 246.0 +/- 127.0, 438.4 +/- 129.4, and 32.2 +/- 5.37 h (mean +/- standard deviation) for JM 1591, JM 1596, and JM 2820, respectively. Systemic clearances based on total concentrations in plasma were low, averaging 0.016 +/- 0.002, 0.015 +/- 0.002, and 0.018 +/- 0.003 liter/h/kg for JM 1591, JM 1596, and JM 2820, respectively. The clearances of unbound compounds from plasma averaged 0.966 +/- 0.136, 0.050 +/- 0.005, and 0.901 +/- 0.165 liter/h/kg for JM 1591, JM 1596, and JM 2820, respectively. For JM 1596, the clearance of unbound compound from the kidneys was lower than the glomerular filtration rate (0.086 liter/h/kg), suggesting this polyoxometalate underwent renal tubular reabsorption. However, JM 1591 and JM 2820 appeared to undergo tubular secretion. The fraction of the dose recovered in urine was 11.5, 46.8, and 10.6% for JM 1591, JM 1596, and JM 2820, respectively. Approximately 5% of the dose of each polyoxometalate was recovered in feces. The steady-state volume of distribution based on total concentrations averaged 1.44 liters/kg for JM 1591, 2.39 liters/kg for JM 1596, and 0.59 liter/kg for JM 2820, indicating moderate to wide distribution throughout the body. All three compounds were detected in various tissues 1 week after single-dose administrations, with the highest levels found in the kidneys and liver. The results of this study indicate that the disposition of polyoxometalates is highly dependent on their molecular structure.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8203845      PMCID: PMC284488          DOI: 10.1128/AAC.38.3.504

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

Review 1.  Plasma and tissue binding considerations in drug disposition.

Authors:  G R Wilkinson
Journal:  Drug Metab Rev       Date:  1983       Impact factor: 4.518

Review 2.  Physiologically based pharmacokinetic modeling: principles and applications.

Authors:  L E Gerlowski; R K Jain
Journal:  J Pharm Sci       Date:  1983-10       Impact factor: 3.534

3.  LAGRAN program for area and moments in pharmacokinetic analysis.

Authors:  M L Rocci; W J Jusko
Journal:  Comput Programs Biomed       Date:  1983-06

4.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

5.  Dose dependent pharmacokinetics of prednisone and prednisolone in man.

Authors:  J Q Rose; A M Yurchak; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

6.  A detailed model of reverse transcription and tests of crucial aspects.

Authors:  E Gilboa; S W Mitra; S Goff; D Baltimore
Journal:  Cell       Date:  1979-09       Impact factor: 41.582

7.  Antiviral activity of polyoxomolybdoeuropate PM-104 against human immunodeficiency virus type 1.

Authors:  Y Inouye; Y Tokutake; T Yoshida; A Yamamoto; T Yamase; S Nakamura
Journal:  Chem Pharm Bull (Tokyo)       Date:  1991-06       Impact factor: 1.645

8.  Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents.

Authors:  N Yamamoto; D Schols; E De Clercq; Z Debyser; R Pauwels; J Balzarini; H Nakashima; M Baba; M Hosoya; R Snoeck
Journal:  Mol Pharmacol       Date:  1992-12       Impact factor: 4.436

9.  Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency.

Authors:  M S Gottlieb; R Schroff; H M Schanker; J D Weisman; P T Fan; R A Wolf; A Saxon
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

10.  Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis.

Authors:  F D Boudinot; W J Jusko
Journal:  J Pharm Sci       Date:  1984-06       Impact factor: 3.534

View more
  2 in total

1.  Non-linear renal and biliary clearances of antiviral polyoxometalates in rats.

Authors:  L Ni; F D Boudinot
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Jul-Sep       Impact factor: 2.441

2.  Pharmacokinetics of anti-HBV polyoxometalate in rats.

Authors:  Juan Wang; Xiaofeng Qu; Yanfei Qi; Jinhua Li; Xiuling Song; Li Li; Dehui Yin; Kun Xu; Juan Li
Journal:  PLoS One       Date:  2014-06-12       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.